Item 9 Labs Corp
OTC:INLB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Item 9 Labs Corp
OTC:INLB
|
US |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of INLB.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
INLB Competitors Multiples
Item 9 Labs Corp Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Item 9 Labs Corp
OTC:INLB
|
701.8 USD | 0 | -0 | -0.5 | -0.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
879.7B USD | 13.8 | 43.7 | 29.5 | 31.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.1B USD | 6.1 | 21.6 | 15 | 18.4 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236B GBP | 5.3 | 30.6 | 16.9 | 23.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.2 | 11.4 | 12.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
295.2B USD | 4.7 | 16.7 | 10.3 | 12.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.9B CHF | 5.2 | 20.8 | 12.9 | 16.6 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.5 | 10.5 | 7.8 | 9.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.1B USD | 2.5 | 19.9 | 7.7 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
116.1B USD | 2.4 | 16.7 | 7.1 | 8.7 |